Vaxcyte Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Vaxcyte, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Revenue & Gross Profit
Revenue0.000.000.000.000.00
Cost of Revenue0.0075.0023.000.000.00
Gross Profit0.00-75.00-23.000.000.00
Operating Expenses
Research & Development476.64332.34169.4578.4173.56
Selling, General & Administrative92.9060.7039.8125.2616.02
Operating Expenses569.55393.04232.26103.6789.58
Operating Income-569.55-393.04-232.26-103.67-89.58
Other Income/Expense
Interest Income109.9962.918.360.340.24
Interest Expense0.000.000.000.01-0.01
Other Income/Expense-4.38-72.13-24.51-1.592.48
Income
Income Before Tax-463.93-402.27-223.49-100.08-89.22
Income Tax Expense0.000.000.000.000.00
Net Income-463.93-402.27-223.49-100.08-89.22
Net Income - Continuous Operations-463.93-402.27-223.49-100.080.00
Net Income - Discontinued Operations0.000.000.000.000.00
EBITDA-562.54-392.10-214.29-96.61-88.18
EBIT-569.55-402.27-223.48-100.07-89.58
Depreciation & Amortization7.0010.172.601.801.41
Earnings Per Share
Basic EPS-4.00-4.00-3.00-2.00-3.00
Diluted EPS-4.00-4.00-3.00-2.00-3.00
Basic Shares Outstanding122.0097.1664.8851.9229.55
Diluted Shares Outstanding122.0097.1664.8851.9229.55